PMS Registry
Company Name
Novartis (Taiwan) Co., Ltd.
Protocol Number
CERL080ATW12
Title of Study
Evaluating the Safety of Myfortic (Mycophenolate sodium) in patients with Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan population
Primary Objective
To describe the safety profile of EC-MPS on LN patients
Number of Sites
6
Period of Study
From:16-Mar-2021 to:31-Mar-2024
Number of Patients
64人
IRB Approval Date
26-Nov-2020
Publication Plan / Date
31-Mar-2025